APR March 2024 - 45
PARTNER PERSPECTIVE
Drug
Nanocarrier
Micelles
Cyclosporine A
Micelles
Nanoemulsions
Nanoparticles
Ciprofloxacin
Cubosomes
Azithromycin
Tacrolimus
Tacrolimus Cerium oxide
Travoprost
Acetazolamide
Vancomycin
Nanoparticle
Liposomes
Ionotropic gellation
Nanosuspensions
Lipid Nanoparticles
Lipid Nanoparticles
Nanoemulsions
Dexamethasone
Microemulsions
Amphotericin B
Nanostructured lipid
carriers
Dry eye
Fungal keratitis
Compritol 888 ATO, Miglyol 812 N, Kolliphor HS15, CTAB, Kolliphor EL
Compritol 888 ATO, lecithin, soybean oil, Poloxamer 188, chitosan
Brand Rx Name
Visudyne®
Restasis®
Retisert®
Durezol®
Besivance®
Tobradex ST®
Prolensa®
Cequa®
Xelpros®
Inveltys®
Eysuvis®
Verkazia®
Formulation
Liposome
Nanoemulsion
Nanoemulsion
Nanoemulsion
Nanosuspension
Nanosuspension
Solution
Nanomicelles
Microemulsion
Nanosuspension
Nanosuspension
Nanoemulsion
Table 2. Ocular nanoparticle drugs approved by FDA
Chemical Name
Verteporfin
Cyclosporine A
Fluclrolone
Difluprednate
Besifloxacin
Tobramycin Dexamethasone
Bromfenac
Cyclosporine A
Latanoprost
Loteprednol etabonate
Loteprednol etabonate
Cyclosporine A
Macular degeneration
Dry eye
Uveitis and macular edma
Postoperative ocular inflammation
Ocular bacterial infection
Ocular inflammation and bacterial infection
Postoperative inflammation and pain
Dry eye
Glaucoma or ocular hypertension
Postoperative ocular inflammation and pain
Dry eye
Vernal keratoconjunctivitis
17
18
Conjunctivitis
Antibiotics
Phytantriol, Poloxamer 407, chitosan, b-glycerophosphate 127
PLGA, Poloxamer 407, PVA
Corneal allograft rejection Poloxamer 188, soy lecithin, cholesterol, hyaluronic acid
Dry eye
Glaucoma
Glaucoma
Ocular bacterial Infection
Dry eye
Gellan gum, aluminum chloride, glycol chitosan
Twin 80, isopropyl alcohol
Phosphatidylcholine, cholesterol, vitamin E, trehalose, erythritol, borate, HPMC
Glyceryl tripalmitate, Eudragit RS100, polyoxyl 15 hydroxystearate, oleic acid, sod. alginate
Cholesterol, Labrafac, Tween 80, phenyl boronic acid, 3-amino-phenyl boronic acid, chondroitin
sulfate, Preciol ATO 5, Compritol 888 ATO, Miglyol 812 N, Kolliphor HS15 and EL, CTAB
9
10
11
12
13
14
15
16
Antibacterial
Dry eye
Table 1. Recent development in nanotechnologies for development of drugs in ocular delivery
Indication
Formulation
Vitamin E, Vitamin E-TPGS, polyoxyl 40 hydrogenated castor oil
mPEG-PLA
Chitosan, Transcutol P, oleic acid, Tween 20
Compritol 888, Tween 80, chitosan, poly (2- ethyl-2-oxazoline)
Reference
5
6
7
8
Therapeutic Indication
Year Approved
2000
2002
2005
2008
2009
2009
2013
2018
2018
2018
2020
2021
www.americanpharmaceuticalreview.com |
| 45
»
http://www.americanpharmaceuticalreview.com
APR March 2024
Table of Contents for the Digital Edition of APR March 2024
Message from the Editor
Editorial Advisory Board
BIOPHARMACEUTICALS - Getting to GMP-Quality Biotherapeutics From Today’s Bench-Scale Continuous Manufacturing Systems: A Gap Analysis
MICROBIOLOGY - Critical Behavioral Attributes and the Application of COM-B Framework in Aseptic Processing
FORMULATION AND DEVELOPMENT - Use of AUC in AAV Analysis in a GMP Setting
FORMULATION AND DEVELOPMENT - Precision Medicine in Clinical Trials: A Statistical Perspective
An Interview with Dan Smithey, PhD President & CEO, Serán
FORMULATION AND DEVELOPMENT - Still Early Days for AI in Drug Discovery...Says Who?
QC Corner - Enhancing Material and Equipment Availability in Production Isolators
BIOPHARMACEUTICALS - Technologies for Aseptic Filling: The Choice is Clear
Vendor Viewpoint - Data Integrity and Rapid Micro Methods: Transforming to a Modern Microbiology Lab
MICROBIOLOGY - Bacterial Spore Formers in Disinfectant Efficacy Testing
Partner Perspective - Nanoparticle Technologies: Enablers for Ocular Drug Delivery
DRUG DELIVERY - Your Nails and You
DRUG DEVELOPMENT - Battling Exorbitance: High Costs in Sickle Cell Gene Therapies and the Imperative of Global Patient Registries for Equity
FORMULATION AND DEVELOPMENT - How Pharma Companies Are Solving Regulatory Challenges with AI-based Technology
Event Preview - CPHI North America
Event Preview - Excipient World 2024
P.I.N. Points
Advertiser's Index
APR March 2024 - CoverTip01
APR March 2024 - CoverTip02
APR March 2024 - Cover1
APR March 2024 - Cover2
APR March 2024 - 1
APR March 2024 - 2
APR March 2024 - 3
APR March 2024 - 4
APR March 2024 - 5
APR March 2024 - Message from the Editor
APR March 2024 - Editorial Advisory Board
APR March 2024 - BIOPHARMACEUTICALS - Getting to GMP-Quality Biotherapeutics From Today’s Bench-Scale Continuous Manufacturing Systems: A Gap Analysis
APR March 2024 - 9
APR March 2024 - 10
APR March 2024 - 11
APR March 2024 - 12
APR March 2024 - 13
APR March 2024 - MICROBIOLOGY - Critical Behavioral Attributes and the Application of COM-B Framework in Aseptic Processing
APR March 2024 - 15
APR March 2024 - 16
APR March 2024 - 17
APR March 2024 - 18
APR March 2024 - FORMULATION AND DEVELOPMENT - Use of AUC in AAV Analysis in a GMP Setting
APR March 2024 - 20
APR March 2024 - 21
APR March 2024 - 22
APR March 2024 - 23
APR March 2024 - FORMULATION AND DEVELOPMENT - Precision Medicine in Clinical Trials: A Statistical Perspective
APR March 2024 - 25
APR March 2024 - 26
APR March 2024 - 27
APR March 2024 - An Interview with Dan Smithey, PhD President & CEO, Serán
APR March 2024 - 29
APR March 2024 - 30
APR March 2024 - FORMULATION AND DEVELOPMENT - Still Early Days for AI in Drug Discovery...Says Who?
APR March 2024 - 32
APR March 2024 - 33
APR March 2024 - QC Corner - Enhancing Material and Equipment Availability in Production Isolators
APR March 2024 - 35
APR March 2024 - BIOPHARMACEUTICALS - Technologies for Aseptic Filling: The Choice is Clear
APR March 2024 - 37
APR March 2024 - 38
APR March 2024 - 39
APR March 2024 - Vendor Viewpoint - Data Integrity and Rapid Micro Methods: Transforming to a Modern Microbiology Lab
APR March 2024 - 41
APR March 2024 - MICROBIOLOGY - Bacterial Spore Formers in Disinfectant Efficacy Testing
APR March 2024 - 43
APR March 2024 - Partner Perspective - Nanoparticle Technologies: Enablers for Ocular Drug Delivery
APR March 2024 - 45
APR March 2024 - 46
APR March 2024 - 47
APR March 2024 - DRUG DELIVERY - Your Nails and You
APR March 2024 - 49
APR March 2024 - 50
APR March 2024 - 51
APR March 2024 - DRUG DEVELOPMENT - Battling Exorbitance: High Costs in Sickle Cell Gene Therapies and the Imperative of Global Patient Registries for Equity
APR March 2024 - 53
APR March 2024 - 54
APR March 2024 - 55
APR March 2024 - FORMULATION AND DEVELOPMENT - How Pharma Companies Are Solving Regulatory Challenges with AI-based Technology
APR March 2024 - 57
APR March 2024 - Event Preview - CPHI North America
APR March 2024 - 59
APR March 2024 - Event Preview - Excipient World 2024
APR March 2024 - 61
APR March 2024 - P.I.N. Points
APR March 2024 - 63
APR March 2024 - Advertiser's Index
APR March 2024 - Cover3
APR March 2024 - Cover4
https://www.nxtbookmedia.com